Menù dei Marcatori

Ipertesto Neoplasie

 

LINKS

 

 

 Scheda a cura di Marco Chilosi  (GYM)         

 

Morbo di Hodgkin 

 

BIBLIOGRAFIA

 
  1. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96(5):1889-99.
  2. Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG. Follicular Hodgkin's disease. Am J Surg Pathol. 1995 19(11):1294-9.
  3. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    J Clin Oncol. 1999;17(3):776-83.
  4. Kanavaros P, Vlychou M, Stefanaki K, Rontogianni D, Gaulard P, Pantelidaki E, Zois M, Darivianaki K, Georgoulias V, Boulland ML, Gorgoulis V, Kittas C. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
    Anticancer Res. 1999;19(2A):1209-16.
  5. Anastasi J, Bauer KD, Variakojis D. DNA aneuploidy in Hodgkin's disease. A multiparameter flow-cytometric analysis with cytologic correlation. Am J Pathol 1987, 128:573-582.
  6. Haber MM, Liu J, Knowles DM, Inghirami G. Determination of the DNA content of the Reed-Sternberg cell of Hodgkin's disease by image analysis. Blood 1992, 80:2851-2857.
  7. Gerdes J, Van Baarlen J, Pileri S, Schwarting R, Van Unnik JAM, Stein H. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 1987, 128:390-393.
  8. Schmid C, Sweeney E, Isaacson PG. Proliferating cell nuclear antigen (PCNA) expression in Hodgkin's disease. J Pathol 1992, 168:1-6.
  9. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I, Lammert H, Demel G, Theil J, Wirth T, Stein H. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95(4):1443-50.
  10. Seitz V, Hummel M, Anagnostopoulos I, Stein H.Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type. Blood. 2001;97(8):2401-5.
  11. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, Stein H.Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin.
    Blood. 1999;94(9):3108-13.
  12. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, Falini B, Dalla-Favera R. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood. 1998;92(7):2220-8.
  13. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B, Sebastiani C, Cattoretti G, Pileri S, Dalla-Favera R, Stein H. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.
    Blood. 2000;95(6):2084-92.
  14. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, Isaacson PG, Pileri S, Stein H. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.
    N Engl J Med. 1997;337(7):453-8.
  15. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, Wirth T, Demel G, Falini B.Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97(2):496-501.
  16. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M.Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol. 1991;5(2):67-73.
  17. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, Barbareschi M, Scarpa A, Mariuzzi GM, Pizzolo G.Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood. 1994;84(12):4295-300.
  18. Kupper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P, Trumper L.MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112(3):768-75.
  19. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G, Rahal D, Pedron S, Benedetti A, Scardoni M, Macri E, Lestani M, Menestrina F, Pizzolo G, Scarpa A.p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood. 1996, 88(10):4012-20.
  20. Sanchez-Beato M, Piris MA, Martinez-Montero JC, Garcia JF, Villuendas R, Garcia FJ, Orradre JL, Martinez P.MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    J Pathol. 1996;180(1):58-64.
  21. Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann ML.Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood. 1999;94(5):1755-60.
  22. Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L.CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001 Feb 1;20(5):590-8.
  23. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dorken B. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94(9):3129-34.
  24. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000;157(3):709-15.
  25. Pizzolo G, Chilosi M, Semenzato G, Caligaris-Cappio F, Fiore-Donati L, Perona G, Janossy G. Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease.Br J Cancer. 1984 ;50(3):415-7.
  26. Pizzolo G, Vinante F, Nadali G, Chilosi M, Semenzato G. Circulating soluble ICAM-1 in patients with Hodgkin's disease. Immunol Today. 1994; 15(3):140-1.
  27. Nadali G, Vinante F, Rigo A, Tecchio C, Morosato L, Zanolin E, Perona G, Chilosi M, Pizzolo G. Correlation between clinical features and circulating levels of soluble intercellular adhesion molecule-1 in Hodgkin's disease. Int J Clin Lab Res. 1995;25(2):84-7.
  28. Chilosi M, Pizzolo G. Biopathologic features of Hodgkin's disease. Leuk Lymphoma. 1995;16(5-6):385-95. Review.
  29. Kadin ME, Agnarsson BA, Ellingsworth LR, Newcom SR. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol. 1990;136(6):1209-14.
  30. Kadin M, Butmarc J, Elovic A, Wong D. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease.
    Am J Pathol. 1993 ;142(1):11-6.
  31. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia.
    Blood. 1999;93(8):2463-70.
  32. Buri C, Korner M, Scharli P, Cefai D, Uguccioni M, Mueller C, Laissue JA, Mazzucchelli L. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood. 2001;97(6):1543-8.
  33. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, Royer HD, Stein H, Dorken B. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood. 1999 ;94(6):2065-71.
  34. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol. 1999;154(6):1685-91.
  35. Chambost H, Van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ, Theate I, Plumas J, Spagnoli GC, Michel G, Coulie PG, Olive D. Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood. 2000;95(11):3530-3.
  36. Kraus MD, Haley J.Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol. 2000;24(8):1068-78.
  37. Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME, Alkan S. Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol. 1999;154(5):1439-47.
  38. Jaffe ES.Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001 ;14(3):219-28. Review.
  39. Menestrina F, Chilosi M, Scarpa A.Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns? Semin Diagn Pathol. 1995;12(3):256-69. Review.
  40. Smolewski P, Niewiadomska H, Los E, Robak T.Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol. 2000;17(3):603-9.
  41. Smolewski P, Robak T, Krykowski E, Blasinska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O.Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
    Clin Cancer Res. 2000;6(3):1150-60.
  42. Brink AA, Oudejans JJ, van den Brule AJ, Kluin PM, Horstman A, Ossenkoppele GJ, van Heerde P, Jiwa M, Meijer CJ.Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol. 1998;11(4):376-83.
  43. Pagnano KB, Vassallo J, Lorand-Metze I, Costa FF, Saad ST.p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am J Hematol. 2001;67(2):84-92.
  44. Nieder C, Petersen S, Petersen C, Thames HD.The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma.
    Ann Hematol. 2001;80(1):2-8.
  45. Smolewski P, Robak T, Krykowski E, Blasinska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O.Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
    Clin Cancer Res. 2000;6(3):1150-60.
  46. Brink AA, Oudejans JJ, van den Brule AJ, Kluin PM, Horstman A, Ossenkoppele GJ, van Heerde P, Jiwa M, Meijer CJ.Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol. 1998;11(4):376-83.
  47. ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, Meijer CJ.Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.
    Leukemia. 2001;15(3):458-64.
  48. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJ. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.
    Blood. 1997;89(4):1376-82.
  49. Hedvat CV, Jaffe ES, Qin J, Filippa DA, Cordon-Cardo C, Tosato G, Nimer SD, Teruya-Feldstein J. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol. 2001 Dec;14(12):1270-6.

 

 

Back to Hodgkin